The latest edition of the HPRA Drug Safety Newsletter is a dedicated issue reminding healthcare professionals (HCPs) of the serious teratogenic risks of valproate-containing medicines (Epilim▼), restrictions for use, contraindication in women of childbearing potential and in pregnancy, details of the pregnancy prevention programme and important individual actions required of each HCP.